Missing: Kanisa Pharmaceuticals's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Kanisa Pharmaceuticals's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Kanisa Pharmaceuticals
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Kanisa Pharmaceuticals is included in 2 Expert Collections, including Cancer.
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Kanisa Pharmaceuticals Frequently Asked Questions (FAQ)
Where is Kanisa Pharmaceuticals's headquarters?
Kanisa Pharmaceuticals's headquarters is located at 12264 El Camino Real, San Diego.
What is Kanisa Pharmaceuticals's latest funding round?
Kanisa Pharmaceuticals's latest funding round is Series A.
How much did Kanisa Pharmaceuticals raise?
Kanisa Pharmaceuticals raised a total of $25M.
Who are the investors of Kanisa Pharmaceuticals?
Investors of Kanisa Pharmaceuticals include InterWest Partners, Lilly Ventures, Montreux Equity Partners, Windamere Venture Partners, New Enterprise Associates and 3 more.
Who are Kanisa Pharmaceuticals's competitors?
Competitors of Kanisa Pharmaceuticals include Zogenix, Constellation Pharmaceuticals, Neos Therapeutics, OcuNexus Therapeutics, Aquinox Pharmaceuticals and 13 more.
Compare Kanisa Pharmaceuticals to Competitors
VGXI is a contract manufacturer of plasmid DNA. The company delivers flexibility, experience, reliability, and value to clients’ challenging programs. The company’s cGMP and non-cGMP products have passed rigorous international regulatory reviews.
Adastra Pharmaceuticals is a private, clinical-stage biopharmaceutical company committed to providing responsible solutions to advance patient care in oncology. Its vision is to identify, develop, and deliver to patients important new therapies for diseases with significant unmet needs. This commitment is epitomized by its lead clinical candidate, zotiraciclib, which is initially being developed for the treatment of high-grade gliomas (HGG) and diffuse intrinsic pontine glioma (DIPG), two forms of brain cancer characterized by Myc overexpression. Adastra possesses a rich history of institutional and academic collaboration, including ongoing clinical research programs with the National Cancer Institute (NCI) and the European Organisation for Research and Treatment of Cancer (EORTC).
CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.
Founded in early 2002 by Avalon Ventures and Domain Associates, Ansata Therapeutics is developing & commercializing novel medicines that capitalize on the Company's industry- leading expertise and intellectual property in molecular transduction. Ansata has several preclinical programs under development in the oncology and neurodegenerative disease areas. The company strives to rapidly advance lead compounds from late-stage preclinical research into clinical development by leveraging its proprietary knowledge of common dermatological diseases.
OcuCure Therapeutics is an ophthalmic pharmaceutical company developing new drugs. The company's lead compound has been formulated as a topical eye drop for both Age-related Macular Degeneration (AMD) and Diabetic Retinopathy (DR). AMD and DR are leading causes of blindness in developed countries. Additionally, the lead compound has potential for use as a prophylactic. The presence of the therapeutic target has been validated in human AMD and DR tissues. This confirms the OcuCure approach for treating ocular angiogensis. The topical eye drop also has demonstrated the ability to cross human corneas in in vitro studies. When the eye drop was administered to animals, the lead compound penetrated all the way back to the retina at clinically significant concentrations without any toxic effects observed. By comparison, the currently available drugs for AMD are administered by a monthly injection into the eye.
Metronome Therapeutics is developing oncology drugs
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.